Humanised antibodies labelled with radionuclides that emit beta-rays

4:

• The conjugate according to claim 1, wherein the nuclide that emits β-rays is iodine-131, yttrium-90, or lutetium-177.

5:

• The conjugate according to claim 1, wherein the conjugate comprises a chelating agent chelated with a radionuclide, and the radionuclide is a metal nuclide that emits β-rays.

6:

• The conjugate according to claim 5, wherein the metal nuclide that emits β-rays is yttrium-90.

7:

• The conjugate according to claim 5, wherein the metal nuclide that emits β-rays is lutetium-177.

8:

• The conjugate according to claim 5, comprising not less than 1 molecule and not more than 8 molecules of the chelating agent per 1 molecule of the antibody.

9:

• The conjugate according to claim 5, wherein the chelating agent site-specifically modifies an Fc region of the antibody via a linker.

11:

• The conjugate according to claim 5, wherein the chelating agent has a structure derived from a compound represented by the following formula (A) or a salt thereof:
• wherein in the formula (A), R11, R13 and R14 are each independently a group consisting of —(CH2)pCOOH, —(CH2)pC5H5N, —(CH2)pPO3H2, —(CH2)pCONH2 or —(CHCOOH)(CH2)pCOOH, one of R12 and R15 is a hydrogen atom, a carboxyl group, or a carboxyalkyl group having 2 or 3 carbon atoms, the other is a substituent for conjugating with the antibody, p is an integer of not less than 0 and not more than 3, R15 is a hydrogen atom when R12 is a substituent for conjugating with the antibody, and R15 is a substituent for conjugating with the antibody when R12 is not a substituent for conjugating with the antibody.

12:

• A radiopharmaceutical comprising the conjugate according to claim 1, as the active ingredient.

13:

• The radiopharmaceutical according to claim 12, that is used for RI internal therapy for cancer.

14:

• The radiopharmaceutical according to claim 13, that is administered to a subject at a dose of not more than 100 MBq/kg one time in the RI internal therapy, wherein the radionuclide is iodine-131.

15:

• The radiopharmaceutical according to claim 13, that is administered to a subject at a dose of not more than 50 MBq/kg one time in the RI internal therapy, wherein the radionuclide is yttrium-90.

16:

• The radiopharmaceutical according to claim 13, that is administered to a subject at a dose of not more than 50 MBq/kg one time in the RI internal therapy, wherein the radionuclide is lutetium-177.